Quality measurement and improvement in rheumatology: Rheumatoid arthritis as a case study

Introduction

In recent years, we have seen significant efforts to understand health care quality in the United States, including rheumatic diseases. Health care reform, as demonstrated through the Affordable Care Act (ACA) and Health Information Technology for Economic and Clinical Health (HITECH) Act, has further accelerated this rapidly evolving field. (1) The formidable tasks of improving quality, enhancing equity, and ensuring value in U.S. health care, remain largely unsolved.

Rheumatologists are affected by programs aimed at driving quality improvement, including performance measurement, public reporting, and tiered payment systems. Many of these programs have focused on rheumatoid arthritis (RA), a condition with rising prevalence and increasing health care costs. In this paper, we review the literature regarding quality measurement and improvement in RA with four aims: 1) to define quality in RA, 2) to delineate the history of RA quality indicator/ measure development, 3) to outline lessons learned from prior RA quality measurement experiences, and 4) to frame the future of RA quality initiatives. In reviewing this literature, we strive to highlight both the achievements and failures in developing and implementing quality measures for RA.

Defining quality in RA

Many quality of care organizations play a role in RA quality measures. These include physician groups (American Medical Association [AMA]’s Physician Consortium for Performance Improvement [PCPI]), government agencies (Centers for Medicare and Medicaid Services [CMS]’s Physician Quality Reporting System [PQRS] and Medicare Stars Program), private health care insurers, and quality measure endorsement organizations (National Quality Forum [NQF]), among others (Table 1)(2). Each of these stakeholders has an important role in measure development, field-testing, endorsement, and reporting for RA. The American College of Rheumatology (ACR) has collaborated with these stakeholders to generate the RA PQRS measures, and has developed detailed policies and procedures for endorsing potential quality measures. (3)

Table 1. Stakeholders in RA quality.

Group	Example	RA quality activities
Physician Specialty Societies (e.g., American Medical Association Physician Consortium for Performance Improvement (PCPI)	Medical leadership in defining health care quality, quality measures development, and physician recognition programs	Collaboration with NCQA and ACR leadership for PCPI approval of 5 RA measures
Non-profit quality organizations	National Committee for Quality Assurance (NCQA)	Healthcare Effectiveness Data and Information Set (HEDIS) measures, such as DMARD use in RA
Medical Certification Boards (e.g., American Board of Internal Medicine [ABIM])	Continuous Professional Development, Practice Improvement Modules (PIMs)	ABIM role in developing PIMS, which include a RA module
Government	Centers for Medicare and Medicaid Services (CMS)	Physician Quality Reporting System (PQRS) with RA measure set (6 QIs)
Third party payors	Measurement programs with incentives and disincentives to health care providers	Tiering, pay-for-performance (P4P), prior authorization programs
Quality Measure Endorsers and Accreditors (e.g., National Quality Forum [NQF], Joint Commission,)	Endorsement and approval of measurement sets	NQF-endorsed RA measures

The Institute of Medicine (IOM) defines quality of care as “the degree to which health care services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge.” (4) Defining and measuring quality in health care is sometimes a difficult process, as only certain aspects of health care are amenable to measurement. Often, these specific and measurable aspects of care are characterized as quality indicators (QIs). A quality indicator (QI) is often framed in an “IF, THEN” format. For example, the QI on disease modifying anti-rheumatic drugs (DMARD) use in RA is “IF a patient has an established diagnosis of RA, THEN the patient should be treated with a DMARD unless contraindication to DMARD, inactive disease or patient refusal is documented”. In this example, the QI defines a process of care (DMARD use in patients with RA) that is strongly linked to an outcome (improved health outcomes among patients).

Translating a QI into a quality measure (QM) allows the measurement of performance in clinical practice. A quality measure (QM) has more detailed specifications that define the exact numerator and denominator for the QI being evaluated: “the percentage of patients age 18 and older who were prescribed, dispensed, or administered at least one ambulatory prescription for a DMARD during the 12-month reporting period”. (5) During the QI process, consideration is given to practical aspects of measurement, such as inclusion criteria (e.g. limiting measures to adult patients with RA), and exclusion criteria (e.g. excluding pregnant women and those with certain co-morbidities).

A QM is therefore a tool that enables the user to quantify the quality of a selected aspect of care by comparing it to a criterion. (6) QMs, and the QIs from which they are derived, are often developed from a combination of literature searches, evidence-based guidelines and recommendations, and expert opinion, through the use of a systematic approach. (7-10) Using RA as an example, potential QMs are categorized around five domains of quality: structure, process, outcome, access, and patient experience. (11-13) Examples of QMs referable to each of these five domains would be: structure – the number of rheumatology clinics in which disease activity score 28 (DAS28) values for RA patients are electronically documented; process – DMARD use in RA; outcome – the number of RA patients in clinical remission one year after diagnosis; access – the percentage of patients with RA who see a rheumatologist within three months of symptom onset in a particular geographic area; and patient experience – RA patient satisfaction with rheumatologist encounter.

QMs can be utilized for at least four purposes: quality improvement, accountability, transparency, and research. (15, 16) The QM on DMARD use in RA has been utilized for all of these purposes: quality improvement - identifying which patients in a practice are not on DMARD therapy and developing strategies for increasing DMARD use, accountability – measuring DMARD use routinely as part of the PQRS RA measure set, transparency – assessing differences in performance by health plans (HEDIS), and research – studying rates of DMARD therapy across different RA populations. Thus, QMs can be important tools to improve clinical practice, standardize measurement across practices, and answer challenging research questions.

A desirable QM has three essential attributes: importance, scientific soundness, and feasibility. (6) Importance relates both to the clinical relevance and the overall public health impact. Scientific soundness encompasses discrete characteristics of a measure, such as validity, reliability and risk-adjustment. Feasibility denotes the practical considerations involved in measuring the QM: are the data readily available, can the measurement process be implemented, and is the cost and burden of data collection known? In the following sections, we use the Physician Quality Reporting System RA measure set to exemplify how these three QM attributes can be applied. (14)

RA quality indicator and quality measure development

The evolution of quality measurement efforts in RA, like other examples throughout the health care system, has been a step-wise, gradual process over the last decade. The first effort can be traced back to research performed by Maclean et al. at UCLA/RAND. (17) In a large national study of RA patients, using process of care measures, researchers demonstrated suboptimal health care quality across the domains of arthritis, co-morbid disease and health maintenance. Higher quality scores were observed if specialists were involved in care. (18) This study was instrumental in defining the extent of the quality problem for patients with RA and laid the foundation for future studies defining and applying RA QIs.

In 2004, a formal QI set for RA was put forth with funding from the Arthritis Foundation (AF) (19, 20) This set was rigorously developed using the RAND/UCLA appropriateness method, which combines systematic literature reviews and expert panel ratings for potential QIs. The resulting 27 RA QIs represent a minimal standard to assess quality of care among RA patients, spanning processes of care such as imaging studies, medication use, exercise, surgery, laboratory monitoring and vaccinations.

This QI development effort in the United States also set a precedent for subsequent international efforts. In 2009, RA QIs focusing on disease course monitoring were developed in the Netherlands, using a modified Delphi method. (21) The 18 final RA QIs were rated according the grade of supporting evidence. (22) These QIs encompassed process measures (N=10), structure measures (N=5), and outcome measures (N=3) for use in daily clinical rheumatology practice. All of the structure and outcome measures (N=8) were supported by level D evidence, indicating reliance on expert opinion. The primary focus of these QIs was a single aspect of rheumatologic care: management of the RA disease course; the generalizability and feasibility of these QIs remains to be field-tested. (8)

Quality measures in RA have been derived largely from two approaches: modifying the early QI efforts outlined above, and developing new measures from clinical guideline recommendations. Many of these efforts were in response to national programs seeking to endorse or apply RA measures in the health care system. RA Quality measures currently used in the U.S. health care system are listed in Table 2. These measures were largely derived from the original 2004 AF measure set and the 2008 RA treatment guidelines. (10, 19, 20) A critical review of this list reveals that many of the measures that have gained early national prominence, have done so because they represent concepts that are easily measured with current data infrastructure. For example, the only measures submitted to the NQF to date reflect data contained within administrative claims. Many broad areas that are critical in evaluating the larger construct of health care quality in RA, such as the appropriate assessment and management of disease activity and functional status are not included, but efforts to examine these important clinical metrics are underway, as discussed below.,

Table 2. Rheumatoid arthritis (RA) quality measures (QMs) used in the United States.

Quality indicat or	Specification	NQF endorsed	HEDIS	PQRS	ACR
Tuberc ulosis screeni ng	Adult patients with RA who have documentation of a tuberculosis (TB) screening performed and results interpreted within 6 months prior to receiving a first course of therapy using a biologic DMARD	No		√
Periodic assess ment of disease activity	Adult patients with RA who have an assessment and classification of disease activity at least once within 12 months.	No		√
Functio nal status assess ment	Adult patients with RA for whom a functional status assessment was performed at least once within twelve months.	No		√
Assess ment and classific ation of disease prognos is	Adult patients with RA who have an assessment and classification of disease prognosis at least once within 12 months.	No		√
Glucoco rticoid manage ment	Adult patients with RA who have been assessed for glucocorticoid use and, for those on prolonged doses of prednisone > 10 mg daily (or equivalent) with improvement or no change in disease activity, documentation of glucocorticoid management plan within 12 months.	No		√
DMARD use in RA	IF a patient has an established diagnosis of rheumatoid arthritis, THEN the patient should be treated with a DMARD unless contraindication to DMARD, inactive disease or patient refusal is documented.	√	√	√
RA treatme nt acceler ation	IF a patient has rheumatoid arthritis and is being treated with a DMARD and there is evidence of increased disease activity or there is evidence of progression of RA bony damage over a 6-month period of time, THEN one of the following should be done: change DMARD dose or route of administration, change DMARD, add an additional DMARD, start or increase dose of glucocorticoids or provide local glucocorticoid injection(s), unless the patient refuses or all of the above are contraindicated.	No			√
Hydroxy chloroq uine annual eye exam	The percentage of patients with RA who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year	√
Methotr exate CBC within 12 weeks	Adult patients with RA who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim	√
Methotr exate serum creatini ne within 12 weeks	Adult patients with RA who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.	√
Methotr exate LFT within 12 weeks	Adult patients with RA who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a LFT in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.	√
RA new DMARD baseline CBC	Adult patients with a diagnosis of RA who received appropriate baseline CBC testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D- Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year.	√
RA new DMARD baseline LFT	Adult patients with a diagnosis of RA who received appropriate baseline LFT (AST or ALT) within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.	√
RA new DMARD baseline serum creatini ne	This measure identifies adult patients with a diagnosis of RA who received appropriate baseline serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D- Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.	√
New RA baseline ESR or CRP within 3 months	This measure identifies adult patients newly diagnosed with RA during the first 8 months of the measurement year who received ESR or CRP lab tests either 4 months (3 months + 1-month grace period) before or after the initial diagnosis.	√
RA annual ESR or CRP	This measure identifies adult patients with a history of RA who have received ESR or CRP lab tests during the measurement year.	√

HEDIS = Health Plan Employer Data and Information Set, PQRS = Physician Quality Reporting System, DMARD = disease-modifying anti-rheumatic drug, CBC = complete blood count, LFT = liver function test, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate

Health Plan Employer Data and Information Set (HEDIS)

The quality measure that has been applied to largest number of Americans with RA pertains to the use of DMARDs. This was the first rheumatology-specific QM incorporated into the Health Plan Employer Data and Information Set (HEDIS). HEDIS encompasses performance measures used in the managed care and insurance industry, providing annual data for QMs across health plans.

A recent analysis of the HEDIS RA DMARD measure by our group has shown that among 90,000 Medicare managed care enrollees with RA, between 2005-2008, 63% received a DMARD. (23) These data provide a birds-eye view of DMARD use in the United States, and suggest disparities across populations. For example, older individuals, Blacks and those with low socioeconomic status were significantly less likely to use a DMARD. In addition, we found wide variations in performance based on health plan with rates ranging from 16-87% even after adjusting for case-mix. Similarly, performance in different geographic regions ranged from 52-71% after adjustment for patient characteristics. Key questions regarding the role of patient characteristics (patient preference, co-morbidities, disease activity) and health care access (accessibility of subspecialty care, cost-sharing for medications and other health plan policies) remain and can only be answered when more clinically detailed data streams become available.

National Quality Forum (NQF)

Over the last several years, the NQF has played an increasingly important role as a national endorsement body for performance measure sets. The NQF was established by an act of Congress in 1999, and structured as a public-private partnership with broad participation from all parts of the health care system, including national, state, regional and local groups that represent patients, purchasers, employers, health care professionals, provider organizations and health plans, among others. Once measures pass the standardized endorsement process of the NQF, they are often disseminated widely throughout the health care system, with the goal of improving the quality of American health care. There have been nine RA QMs endorsed by NQF (in addition to the original RA DMARD measure), seven regarding drug safety and two evaluating baseline and annual erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) testing.

Each of these nine NQF-endorsed measures was submitted by Resolution Health, Inc., a private company that provides services to both health insurance plans and employers. The drug safety measures are summarized in Table 2. Most of these drug safety QMs can be easily measured through claims (billing) data available to health insurance companies, thus increasing their feasibility.

Although feasible to measure, several methodological questions remain regarding these recently endorsed measures. For instance, consideration of the measurement period around a particular QM cannot be understated. A study assessing a QM for follow-up lab monitoring through the EHR for RA patients initiating DMARDs, found that performance on this QM was 35%, 48% or 60% depending on the lab interval measurement methodology used. (24) This study illustrates the importance of developing and standardizing the methodology used in lab monitoring QMs.

Questions such as the appropriate interval for patients taking various doses remain unanswered (e.g. do patients with no co-morbidities taking 7.5 mg of methotrexate a week require identical monitoring to those with co-morbid conditions taking 20 mg per week?). In a recent systematic review, the scientific basis for most laboratory monitoring practices for rheumatic drugs was found to be weak and largely based on expert consensus. (25) In order to utilize lab monitoring QMs in routine clinical practice, several steps must occur: first is the development of a rigorous scientific evidence base to support monitoring recommendations, second is the determination of the appropriate modality (i.e. CBC and LFTs) and timing (the minimal interval for performing testing) of monitoring, and third is the methodologic research on measure specification. These considerations are crucial in defining the next generation of drug safety monitoring QMs in RA.

Physician Quality Reporting System (PQRS) and Registry reporting for RA QIs

PQRS is a Centers for Medicare and Medicaid Services (CMS) voluntary quality reporting program with bonus payment incentives. (26) There are six RA QIs that comprise the RA measure set for PQRS (Table 3). Five of the six PQRS RA measures are not yet endorsed by the NQF; they were developed in collaboration between the ACR and NCQA as well as the AMA’s PCPI and based on the ACR’s 2008 recommendations for RA.

Table 3. Physician Quality Reporting System (PQRS) RA QI measure set and snapshot of 2009 PQRS data.

QI	2009 RCR Data N and % measure met	Feasibility	Scientific Soundness		Comments	Solutions for improvement
			Reliability	Validity
Tuberculosis screening	N=1,714 (92% measure met)	Moderate	High	Moderate	Dependent on clear documentation of Biologic DMARD being 1st course 2008 ACR guidelines do not specify that PPD screening occur ≤ 6 months of medication start as compared to QI which denotes ≤ 6 month timeframe	Modification of measure specification around timeframe of PPD screening (i.e. ≤ 12 months for example)
Periodic assessment of disease activity	High N=929 (15% measure met) Moderate N=2,205 (35% measure met) Low N=3,157 (50% measure met)	Moderate	High	High	Dependent on rheumatologist use of standardized tool (i.e. DAS28, CDAI, etc.) to classify disease activity as remission, low, moderate, or high	Ensure that all rheumatologists integrate the use of a standardized disease activity tool into routine clinical practice
Functional status assessment	N=6,131 (79% measure met)	Moderate	High	High	Dependent on rheumatologist use of standardized tool (i.e. HAQ, MDHAQ, etc.)	Ensure that all rheumatologists integrate the use of a standardized functional status assessment tool into routine clinical practice
Assessment and classification of disease prognosis	Good N=4,051 (52% measure met) Poor N=2,042 (26% measure met) Not assessed N=1,667 (22% measure met)	Low	Low	Low	Dependent on rheumatologist use of “good” versus “poor” language to describe RA Data elements to define prognosis can vary over time (i.e. disease activity) and may have been assessed years prior to date of QI measurement (i.e. RF/CCP measurement at initial diagnosis) The classification of RA prognosis into “good” versus “poor” is not part of routine clinical practice	Modification of measure specification to outline parameters for determining “good” versus “poor” instead of relying on actual terms
Glucocorticoi d (GC) management	Data not available	Low	Moderate	Moderate	Dependent on incorporation of multiple discrete data elements into complex algorithm (i.e. active glucocorticoid prescription, specific dose and duration of GC use, indication for GC, documentation of GC management plan in note) GC prescriptions in medical record may not reflect current use of GCs by patients and may not corroborate with GC dose/duration listed in rheumatologist notes	Encourage standardized documentation of GC prescriptions entered in medical record by rheumatologists Consider significant modification of actual measure specification
DMARD use in RA	N=7,260 (93% measure met)	√	√	√		N/A

The role of clinical registries in facilitating quality reporting is growing. A clinical patient registry is an electronic system that helps record key aspects of patient care, including QMs. Collecting meaningful clinical data through the use of registries is a powerful way to measure and improve quality as the data captured is richer than administrative data. The strengths of utilizing clinical registries are patient tracking over time, observation of trends for directed quality improvement initiatives, and participation in national quality reporting programs such as PQRS. Since claims (billing) data can be fraught with error and manual chart review can be expensive and time-consuming, registries offer the ability to more readily capture the fundamental data elements required for quality reporting. That being said, in order to report to registries, manual chart review is required and understanding how EHRs can successfully interface with registries for ease of reporting is an important area.

Many specialty societies, the American College of Cardiology and the American Thoracic Society for example, are participating in registry reporting. They have conducted research and implemented impressive quality improvement programs through their registries, and these can certainly serve as a useful model for the field of rheumatology moving forward. The ACR has developed and launched the Rheumatology Clinical Registry (RCR) to facilitate quality reporting for PQRS for practicing rheumatologists. (27) Data from 2009 PQRS reporting reflects over 7,800 RA patients cared for by 240 providers from 125 practices. (28) A snapshot of five of the six RA QIs reported in the measure set is shown (Table 3). The RCR carries great promise for facilitating quality reporting and providing an overall representation of the quality of RA care. The RCR currently is not a nationally representative sample of RA patients that may inform clinical research since the sample derives from self-selected practices that participate in quality reporting. As participation grows, the role of the RCR in both quality initiatives and research will likely grow.

Many of the measures included in the PQRS RA measure set have not been extensively field-tested or validated, and several challenges in the measurement of the existing RA measures have emerged. Concerns have been raised about both the scientific soundness and feasibility of some of the PQRS RA measure set. Table 3 outlines some of the challenges encountered to date applying the PQRS RA measures, in the context of importance, scientific soundness (reliability, validity), and feasibility.

The role of electronic health records (EHRs) in RA QI measurement

Although EHRs hold promise in improving quality, many challenges remain ahead in realizing their full potential. In order to effectively assess performance on quality measures, the data elements required for numerator and denominator specifications must be easily extractable from the EHR. (29) An evaluation of the Veterans Affairs (VA) EHR, where all patient data is stored electronically, studied 3 RA QIs: DMARD use in RA, RA core data set, and RA treatment acceleration. (30) Some of the key requisite data elements, such as joint count, functional status assessment, and quantitative evaluation of x-rays are not typically entered in the EHR as structured data; thus they cannot be obtained easily from the EHR for quality reporting. Aside from these practical considerations, larger questions also remain about the most effective means of utilizing EHRs to improve quality. (31) (32)

In the case of RA, health information technology can be developed to assist rheumatologists with joint counts and disease activity assessments in rheumatology practice. (33-35) It is imperative that EHRs integrate tools to facilitate the documentation, measurement and reporting of QMs to help rheumatologists care for RA patients. In addition, the alignment of these EHR tools with electronic registry reporting, such as the RCR, are important steps to help busy, practicing clinicians caring for patients with RA participate in national quality improvement reporting initiatives.

The successful use of EHR tools does require bioinformatics expertise, time, and funding for development; and physician training, workflow considerations and added time during the office visit for implementation into routine clinical practice.(36) (37) Once these changes are made and adapted in clinical practice, providers may find that caring for practice of RA patients is easier. For example, a practice can decide to use a standardized disease activity assessment tool at each RA patient visit, enter the disease activity score in the EHR, and engage the patient in observing trends in RA disease activity over time.(38) Meaningful use of an EHR is the ability of the EHR to be used in a meaningful manner, to allow exchange of health information electronically for quality improvement and to be utilized for submission of clinical quality measures. (39) Not only are these innovations potentially helpful in shared medical decision making between the patient and provider, but they are important for achieving meaningful use of the EHR. (40)

Lessons learned from prior RA quality measurement experience

In order to develop the next generation of RA QMs, we must critically appraise the literature on existing RA measures. Above, we have summarized some of the key lessons learned from QMs that have gained national prominence in RA, including those endorsed by NQF, NCQA/HEDIS, NCQA/PCPI and the ACR. Most of the RA measures currently in use are process based and not outcome based. In chronic diseases such as RA, it can be difficult to develop, measure, and define QIs assessing outcomes of care. In addition, outcomes may take years to occur and are influenced by a multitude of factors often not under the direct control of the patient, provider, or health care system. However, despite these challenges, the ultimate goal of RA treatment strategies is to improve a variety of outcomes for RA patients, and we anticipate that outcome measures will likely be introduced in the coming decade. In a recent landmark editorial, Michael Porter explained that providing high-value in health care delivery rather than simply focusing on quality, involves incorporating outcomes of care as they relate to cost, while centering care around the individual patient.(41)

Importance of detailed specification of QMs

One currently used RA quality measure is laying the groundwork for outcome measures in RA. The RA treatment acceleration measure is outlined in Table 2. This process measure is in part based on objective outcomes: disease activity and radiographic progression. Several studies have assessed performance on this process of care, with adherence ranging from 50-85%. (42-44) Important lessons in the specification of this measure have become apparent: variation in measure performance may relate to the level of disease activity (moderate or severe), duration of time patient is at disease activity level (months), and time allotted to the rheumatologist for an intervention to occur. (42) That is, if a patient has severe disease activity that is sustained over a longer period of time, or if this measure is assessed at six months rather than three months, performance on the measure will likely be higher. There are several factors that may influence the decision of a rheumatologist to escalate RA care, in addition to disease activity or radiographic progression. (45) Future testing of the RA treatment acceleration measure will require detailed specifications in order to standardize this QI over different populations.

Applicability of RA QMs to rheumatologists versus primary care physicians

In addition to the experiences gained in measure development, specification and validation, the experience to date has also shown that different measures may have applicability to different structural levels of the health care system. For example, as outlined in Table 4, performance on the RA DMARD measure varies from 30-94%, depending on study design (administrative data versus manual chart review), geographic location, type of insurance plan, time period, and health delivery system (Table 4). (42, 44, 46-49) An important lesson learned from application of this QM is that its utility in assessing quality in those who have access to subspecialty care (e.g. those already under the regular care of rheumatologists) is likely limited, as 90% of these patients are taking a DMARD. This measure may be more useful when applied to nationally representative samples of patients with RA where access to subspecialty care may be uneven and geographic and socioeconomic determinants of DMARD use may become apparent.

Table 4. Performance on three rheumatoid arthritis (RA) quality measures (QMs).

RA QMs	Population	Findings
DMARD use in RA	Claims data Medical record review	30-63% (46) (47) (23, 48) 85-94% (42) (44) (49) (43)
RA treatment acceleration*	Medical record review	46% with moderate disease activity had treatment acceleration (42) 80% with severe disease activity had treatment acceleration (42) 85% RA treatment acceleration (44) 50-64% treatment acceleration (43)
RA core data set**	Medical record review	69% RA core data set (44) Joint exam: 98%, functional status: 83%, global assessment: 91%, ESR or CRP: 66%, pain: 92% (43)

^*See Table 2.

^**RA core data set = IF a patient has a diagnosis of RA, THEN each of the following should be documented within 3 months of diagnosis and at appropriate time intervals thereafter: a joint exam, functional status, disease activity (presence/ absence of synovitis, ESR/ CRP) and pain (20)

The future of RA quality initiatives

In the preceding sections, we have highlighted various RA quality measure development efforts and the current associated data systems used in U.S. measurement efforts. As our experience grows, both measure and data system development will be an iterative process, where we build on successful efforts and discard those that were well-intentioned but less feasible or valid. At the national level, RA measures that are NQF-endorsed are already being applied by payors and the government to assess quality. As the number of QMs grows and physician performance incentive programs expand, it will become essential to find ways to incorporate quality measurement into routine clinical practice. An example of a performance incentive program is pay-for-performance (P4P), a mechanism designed to tie a proportion of a physician’s remuneration to performance on pre-specified QMs. (50) Several challenges have been identified in engaging specialist physicians in performance incentive programs: the development of meaningful quality metrics, the question of accountability between different providers caring for the same patient, the nuances of appropriate risk-adjustment, the information technology infrastructure to extract quality data, and the need for robust EHRs capable of facilitating quality measurement. (51)

Despite these potential limitations, there are several key steps to measure and improve the quality of care provided to their RA patients. These steps include: identifying areas where there are gaps in quality, understanding the clinical practice process changes that must occur, learning the methods for process redesign, and espousing performance measurement. (52) Continuous quality improvement (CQI) methods such as Plan-Do-Study-Act (PDSA) cycles can be employed to perform numerous small tests of change with the goal of making improvements without disrupting large processes of care. (36, 53, 54) An example of this would be integrating patient history and patient and physician-reported disease assessments dictation templates for all RA patients. (55)

On a broader scale, system-level process improvement involves thinking about the experience of health care delivery for a particular disease, such as RA, across the entire continuum of care – how does a patient with RA have his/her needs addressed by the health care system? (37) RA is the prototypical chronic disease, cared for by multiple physicians (primary care physician, rheumatologist, orthopedist, etc.) and health care providers (physician, nurse, medical assistant), and in various health care delivery settings (outpatient – rheumatology clinic, physical therapy, inpatient). The Wagner model of chronic illness provides a framework for thinking about how to improve the quality of care for RA patients. (56) This model stresses four key components: 1) provide patients with self-management support to increase self-efficacy, 2) reorganize the practice system and team function to help meet chronic illness patient needs, 3) develop and implement evidence-based guidelines with education and reminders for providers, and 4) augment information systems to help create patient disease registries for tracking and providing feedback on performance (Figure 1). (57)

Figure 1. Wagner model of chronic illness.

This model of chronic illness stresses four key components: 1) provide patients with self-management support to increase self-efficacy, 2) reorganize the practice system and team function to help meet chronic illness patient needs, 3) develop and implement evidence-based guidelines with education and reminders for providers, and 4) augment information systems to help create patient disease registries for tracking and providing feedback on performance. It serves as a framework for guiding RA quality improvement efforts.

The foundation of Wagner’s model is a productive interaction between the patient and the practice team. One can apply the Wagner model to measure and improve upon existing RA QIs to ultimately enhance the quality of care provided to RA patients (Table 5). For example, one way to reorganize the practice system and team to meet needs of the RA patient would be to think about how best to capture information on disease activity assessment. Routinely measuring and acting upon changes in disease activity is a central focus of RA management; therapeutics have evolved such that the goal of therapy is clinical remission. (58) Two of the RA measures, disease activity assessment and treatment acceleration, rely upon the regular assessment of disease activity in routine clinical practice. If patients could provide a global health assessment and self-report joint count either prior to the visit (i.e. web-based tool) or at the point-of-care (i.e. paper or electronic questionnaire), this data could be more readily assimilated into the overall RA management plan during the office visit. (59)

Table 5. Wagner model of chronic illness applied to RA for improving quality of care through process improvement.

Wagner model component	RA QI	Example of process improvement
Patient self-management support	Functional status assessment	Routine questionnaires (paper or electronic) at each RA office visit for data collection and tracking of trends over time with patient and physician feedback using standardized instruments (HAQ, MHAQ, etc.)
Reorganizing practice system and team to meet needs of chronic illness patient	Disease activity assessment RA treatment acceleration	Web-based or point-of- care routine disease activity evaluation using standardized instrument (DAS28, CDAI, RADAI, etc.)
Evidence-based guidelines with provider education	DMARD use	Clinical decision support physician reminders in EHR for patients with RA not on DMARD therapy
Creating patient disease registries	Glucocorticoid management	Outreach efforts by nurse case manager to registry of all RA patients on long-term glucocorticoids for osteoporosis prevention, screening and treatment

Conclusions

There is consensus among all stakeholders that we must work to improve quality and value in the U.S. health care system. Quality measurement and improvement efforts hold great promise and have begun to revolutionize the care provided in certain settings. The dramatic decrease in catheter-related bloodstream infections in hospitals across the United States is a prominent example of how implementation of a standardized checklist can significantly improve the quality of care. (60) In order for the potential to be realized in other areas, especially in outpatient care for most chronic diseases, we have our work cut out for us. Basic methodological issues include the development of sound important measures. Practical concerns are barriers in creating a data infrastructure and large-scale systems improvement for instituting meaningful change.

The federal government has outlined a National Quality Strategy that includes seven key elements: safer care, effective care coordination, person and family centered care, prevention and treatment of leading causes of mortality, supporting better health in communities, and making care more affordable. (61) The mission of the NQF is aligned with the National Quality Strategy to achieve these goals. For patients with RA, a prevalent chronic disease with fluctuations in disease course over time, the first step is the development of a set of important, scientifically sound yet feasible QMs. Rheumatologists should lead the way in scrupulously developing and field-testing new measures that can be submitted to organizations such as the National Quality Forum for endorsement. Active engagement in measure development and submission will ensure that clinically meaningful measures that more closely reflect high quality of care in RA are included in these key measure sets. Health information technology innovations should be integrated with EHRs to facilitate QM documentation, measurement and performance improvement in routine clinical practice. Collaborations among stakeholders, both within the United States and internationally, around RA management guidelines can help solidify the evidence-base from which QMs are generated. As the healthcare landscape continues to change rapidly, the field of rheumatology can be poised to take a leadership role in defining, measuring and improving the quality of care for RA patients.